Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS, Rodrigues NB, Lipsitz O, Nasri F, Gill H, Lui LM, Subramaniapillai M, Kratiuk K, Teopiz K, Ho R, Lee Y, Mansur RB, Rosenblat JD. McIntyre RS, et al. Among authors: kratiuk k. J Psychopharmacol. 2021 Feb;35(2):128-136. doi: 10.1177/0269881120954048. Epub 2020 Oct 11. J Psychopharmacol. 2021. PMID: 33040665
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
McIntyre RS, Lipsitz O, Rodrigues NB, Lee Y, Cha DS, Vinberg M, Lin K, Malhi GS, Subramaniapillai M, Kratiuk K, Fagiolini A, Gill H, Nasri F, Mansur RB, Suppes T, Ho R, Rosenblat JD. McIntyre RS, et al. Among authors: kratiuk k. Bipolar Disord. 2020 Dec;22(8):831-840. doi: 10.1111/bdi.12941. Epub 2020 Jul 8. Bipolar Disord. 2020. PMID: 32406161
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence.
Rodrigues NB, McIntyre RS, Lipsitz O, Lee Y, Cha DS, Nasri F, Gill H, Lui LMW, Subramaniapillai M, Kratiuk K, Lin K, Ho R, Mansur RB, Rosenblat JD. Rodrigues NB, et al. Among authors: kratiuk k. Expert Opin Drug Saf. 2020 Aug;19(8):1031-1040. doi: 10.1080/14740338.2020.1776699. Epub 2020 Jun 15. Expert Opin Drug Saf. 2020. PMID: 32539491
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS, Rodrigues NB, Lee Y, Lipsitz O, Subramaniapillai M, Gill H, Nasri F, Majeed A, Lui LMW, Senyk O, Phan L, Carvalho IP, Siegel A, Mansur RB, Brietzke E, Kratiuk K, Arekapudi AK, Abrishami A, Chau EH, Szpejda W, Rosenblat JD. McIntyre RS, et al. Among authors: kratiuk k. J Affect Disord. 2020 Sep 1;274:903-910. doi: 10.1016/j.jad.2020.05.088. Epub 2020 May 26. J Affect Disord. 2020. PMID: 32664031
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Rodrigues NB, McIntyre RS, Lipsitz O, Cha DS, Lee Y, Gill H, Majeed A, Phan L, Nasri F, Ho R, Lin K, Subramaniapillai M, Kratiuk K, Mansur RB, Rosenblat JD. Rodrigues NB, et al. Among authors: kratiuk k. J Affect Disord. 2020 Nov 1;276:570-575. doi: 10.1016/j.jad.2020.07.083. Epub 2020 Jul 20. J Affect Disord. 2020. PMID: 32871688
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O, McIntyre RS, Rodrigues NB, Kaster TS, Cha DS, Brietzke E, Gill H, Nasri F, Lin K, Subramaniapillai M, Kratiuk K, Teopiz K, Lui LMW, Lee Y, Ho R, Shekotikhina M, Mansur RB, Rosenblat JD. Lipsitz O, et al. Among authors: kratiuk k. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 8;105:110126. doi: 10.1016/j.pnpbp.2020.110126. Epub 2020 Oct 5. Prog Neuropsychopharmacol Biol Psychiatry. 2021. PMID: 33031861
Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O, McIntyre RS, Rodrigues NB, Lee Y, Gill H, Subramaniapillai M, Kratiuk K, Nasri F, Mansur RB, Rosenblat JD. Lipsitz O, et al. Among authors: kratiuk k. CNS Spectr. 2022 Jun;27(3):322-330. doi: 10.1017/S1092852920002102. Epub 2020 Dec 3. CNS Spectr. 2022. PMID: 33267928
27 results